Atopic Dermatitis Biologic Denied: Appeal Guide
Eczema biologic denied by insurance? Appeal using EASI/SCORAD scores, failed topical records, and AAD guidelines for Dupixent, Cibinqo, or Adbry.
Atopic dermatitis (AD), commonly known as eczema, is a chronic, relapsing inflammatory skin disease that causes intense itching, skin barrier dysfunction, sleep disruption, and significant psychological distress. For patients with moderate-to-severe AD, biologic and targeted systemic therapies — including dupilumab (Dupixent), tralokinumab (Adbry), abrocitinib (Cibinqo), and upadacitinib (Rinvoq) — have transformed treatment outcomes. Insurance denials for these agents are common, and the clinical case for appeal is strong.
Why Insurers Deny Atopic Dermatitis Biologics
Incomplete step therapy. Insurers require documented failure of topical therapies — emollients, topical corticosteroids (TCS) of various potencies, topical calcineurin inhibitors (tacrolimus/pimecrolimus), and topical PDE4 inhibitors (crisaborole/roflumilast) — before approving a biologic or advanced systemic agent. Some payers also require a trial of phototherapy or traditional systemic immunosuppressants (cyclosporine, methotrexate, mycophenolate mofetil, or azathioprine, which are used off-label in AD).
Severity not documented with objective scores. Most payer criteria specify moderate-to-severe disease, requiring objective scoring with EASI (Eczema Area and Severity Index), SCORAD (SCORing Atopic Dermatitis), IGA (Investigator's Global Assessment), or DLQI (Dermatology Life Quality Index). Without these scores, the denial cites insufficient documentation of severity.
Non-preferred agent. Dupixent is the most established agent and may be preferred over JAK inhibitors (abrocitinib, upadacitinib) for first-line advanced therapy on some formularies.
Building Your Clinical Appeal
Document Objective Disease Severity
Your dermatologist should calculate and include validated severity scores:
EASI score: Ranges 0–72; moderate disease is typically 7.1–21, and severe disease is >21. Clinical trials for dupilumab required EASI ≥16 at baseline.
SCORAD: Ranges 0–103; moderate disease is 25–50, severe is >50. This tool combines extent (BSA), intensity, and subjective symptoms (itch, sleep loss).
IGA: A 5-point scale; IGA 3 (moderate) or 4 (severe) is the standard threshold for advanced therapy.
DLQI: Score ≥10 confirms large or very large quality-of-life impact. AD-related sleep disruption (quantified in SCORAD) is also a powerful quality-of-life argument.
Request that your dermatologist formally document these scores in the letter of medical necessity if they aren't already in visit notes.
Document Topical Therapy Failures
Create a detailed timeline of topicals tried and failed:
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Emollients and skin barrier therapy: Document regular use of thick emollients (petroleum jelly, ceramide creams) as the foundation of AD care and their inadequacy for controlling moderate-to-severe disease.
Topical corticosteroids: Document specific agents used (low, mid, and high potency), duration, areas of application, and outcomes. If TCS use was limited by side effects (skin atrophy, striae, hypothalamic-pituitary-adrenal suppression — particularly important for facial, groin, or axillary disease), document this explicitly.
Topical calcineurin inhibitors (TCIs): Tacrolimus 0.03% or 0.1% ointment (Protopic) and pimecrolimus 1% cream (Elidel) — document whether these were tried and at what duration. Note intolerance (burning sensation) if applicable.
Topical PDE4 inhibitors: Crisaborole (Eucrisa) and roflumilast (Zoryve) — note if tried and outcome.
Phototherapy: If narrowband UVB phototherapy was tried or was inaccessible (distance to facility, 3x/week schedule impractical), document this.
Systemic immunosuppressants: If cyclosporine, methotrexate, or other off-label systemic agents were tried, document dose, duration, response, and discontinuation reasons (toxicity, monitoring burden, inadequate response). If they weren't tried because of contraindications (e.g., renal disease contraindicated with cyclosporine), state this.
Cite AAD Guidelines
The American Academy of Dermatology's AD clinical practice guidelines endorse dupilumab and other FDA-approved advanced systemic therapies for moderate-to-severe AD in patients who have had inadequate response to topical therapies and/or phototherapy. The guidelines explicitly note that dupilumab has a favorable safety profile compared to traditional systemic immunosuppressants. Cite these guidelines by name in your appeal and have your physician attest that your case meets criteria.
Quality-of-Life Arguments
AD-related sleep deprivation, anxiety, depression, and social isolation are well-documented. The burden of disease on pediatric patients and their families is substantial. Include DLQI score, documentation of sleep disruption, and any notes about psychological impact. For children, the Children's Dermatology Life Quality Index (CDLQI) is the validated tool.
Special Considerations for JAK Inhibitors
Abrocitinib (Cibinqo) and upadacitinib (Rinvoq) are JAK inhibitors with boxed warnings that some payers use to restrict them to patients who have failed dupilumab. If your prescriber prefers a JAK inhibitor for specific clinical reasons, the letter of medical necessity should address the clinical rationale (e.g., faster onset for urgent cases, combined atopic disease profile, dupilumab intolerance or inadequate response).
Resources
- National Eczema Association (NEA) (nationaleczema.org) — insurance advocacy toolkit, Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization support
- Manufacturer assistance: Sanofi/Regeneron (Dupixent MyWay), LEO Pharma (Adbry Patient Support), Pfizer (Cibinqo patient support), AbbVie (Rinvoq patient assistance) — all provide copay cards and free drug during appeals
Organized documentation of severity scores and step therapy failures wins the overwhelming majority of AD biologic appeals.
Fight Back With ClaimBack
ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word. Fight your denial at ClaimBack →
Related Reading:
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides